President and CEO, Ambys Medicines
Jeff Jonker joined Ambys Medicines as CEO in 2018 to lead the South San Francisco-based biotech’s efforts to pioneer regenerative medicines for severe liver diseases. Jeff joined Ambys from NGM Bio, where he served as President, leading advancement of the company’s robust multi-therapeutic area pipeline and helping orchestrate its broad, multi-year research and development collaboration with Merck. Prior to joining NGM Bio, Jeff was Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG), and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, Jeff was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high-tech industries.
Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.